EVALUATION of GINGIVAL CREVICULAR FLUID and SERUM ASPROSIN LEVELS in OBESE and NORMAL-WEIGHT INDIVIDUALS with PERIODONTITIS

Evaluation of Serum and Gingival Crevicular Fluid Asprosin Levels in Obese and Normal-Weight Patients with Periodontitis

Obesity and periodontitis are chronic inflammatory diseases that share common pathological mechanisms. Asprosin, a novel adipokine discovered in 2016, has not been extensively studied in relation to periodontal tissues. In our study, we investigate the levels of asprosin in both serum and gingival crevicular fluid of patients with obesity and those of normal weight who have periodontitis. Additionally, our research aims to clarify the pathophysiological mechanisms linking periodontitis and obesity by examining local and systemic levels of TNF-α, IL-6, and asprosin, alongside clinical periodontal parameters.

Study Overview

• Status: Completed
• Conditions: Obesity; Periodontitis
• Intervention / Treatment: Other: Participants are not assigned an intervention as part of the study.

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• Turkey
  • Ankara, Turkey, 06490
    • Gazi University Faculty of Dentistry

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients were recruited from the Periodontology Clinic at Gazi University Faculty of Dentistry between August 2023 and August 2024. All participants who met the inclusion criteria were included in the study. Before their participation, the study's purpose and methods were explained, and written informed consent was obtained.

Description

Inclusion Criteria:

1. Willingness to participate in the study.

2. Weight classification:

   • Obese individuals: Body mass index (BMI) of 30 kg/m² or higher.
   • Normal-weight individuals: BMI between 18.5 and 24.9 kg/m².

3. Periodontal health status:

   • Bleeding on probing: less than 10%.
   • Periodontal pocket depth: less than 3 mm.
   • No sites showing attachment loss or alveolar bone loss on radiographs.

4. For individuals with periodontitis:

   • At least two non-adjacent teeth must show signs of interdental attachment loss.
   • Periodontal pocket depth greater than 3 mm.

Exclusion Criteria:

1. Individuals who have received periodontal therapy, any oral decontamination treatment, or antibiotics or steroids in the six months prior to the start of the study.
2. Individuals who are pregnant or breastfeeding.
3. Individuals diagnosed with rheumatoid arthritis or lupus erythematosus.
4. Individuals with a medical history of radiation or cancer therapy.

5. Patients with diabetes, defined by:

   • Hemoglobin A1c (HbA1c) level greater than 6.5%.
   • Fasting blood glucose (FBG) greater than 126 mg/dL.
   • An abnormal oral glucose tolerance test (OGTT).
6. Smokers.

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Obese individiuals with periodontitis	Other: Participants are not assigned an intervention as part of the study.; Participants are not assigned an intervention as part of the study.
Obese individuals with periodontal healthy	Other: Participants are not assigned an intervention as part of the study.; Participants are not assigned an intervention as part of the study.
Normal-weight Individuals with Periodontitis	Other: Participants are not assigned an intervention as part of the study.; Participants are not assigned an intervention as part of the study.
Normal-weight Individuals with periodontal health	Other: Participants are not assigned an intervention as part of the study.; Participants are not assigned an intervention as part of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biyomarker levels	All groups' GCF and serum levels of asprosin, TNF-α, and IL-6 levels	08.10.2023-08.10.2024

Collaborators and Investigators

• Sponsor: Gazi University
• Collaborators: Gazi University Scientific Research Unit
• Investigators: Study Director: Aysen Bodur, Professor, Gazi University Faculty of Dentistry Department of Periodontology

Study record dates

Study Major Dates

• Study Start (Actual): August 8, 2023
• Primary Completion (Actual): August 10, 2024
• Study Completion (Actual): August 10, 2024

Study Registration Dates

• First Submitted: March 11, 2025
• First Submitted That Met QC Criteria: March 11, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 11, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: Obesity; Periodontitis; Asprosin; Chronic Inflammatory Diseases
• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases; Cardiovascular Diseases; Heart Diseases; Genetic Diseases, Inborn; Connective Tissue Diseases; Congenital Abnormalities; Cardiovascular Abnormalities; Heart Defects, Congenital; Abnormalities, Multiple; Bone Diseases, Developmental; Periodontitis; Marfan Syndrome
• Other Study ID Numbers: E-21071282-050.99-720599

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No